Skip to main content

Table 1 Comparison between both SLE groups (with and without LN) regarding demographic, laboratory and clinical characteristics

From: Association of anti-nuclesome and anti C1q antibodies with lupus nephritis in an Egyptian cohort of patients with systemic lupus erythematosus

Parameter
mean ± SD or n (%)
Group I
(n = 40)
Group II
(n = 40)
t/x2 P value
Demographic features Age (year) 29.0 ± 7.2 32.5 ± 9.4 1.756 0.083
Disease duration (year) 4.4 ± 3.7 6.8 ± 5.6 2.280 0.025
Male/ Female 6 (15) /34 (85) 1 (2.5) /39 (97.5) 3.914 0.048
Clinical features Arthritis 34 (85.0) 38 (95.0) 2.200 0.136
Malar rash 25 (62.5) 25 (62.5) 0.00 1.000
Fever 22 (55.0) 17 (42.5) 1.251 0.263
Pleurisy 21 (52.5) 21 (52.5) 0.000 1.000
Oral ulcers 17 (42.5) 21 (52.5) 0.802 0.370
Alopecia 17 (42.5) 17 (42.5) 0.000 1.000
Photosensitivity 13 (32.5) 18 (45.0) 1.317 0.251
Vasculitis 10 (25.0) 4 (10.0) 3.117 0.077
APS 10 (25.0) 9 (22.5) 0.069 0.793
Neurological manifestations 9 (22.5) 11 (27.5) 0.267 0.606
Pericarditis 6 (15.0) 4 (10.0) 0.457 0.499
Discoid rash 2 (5.0) 4 (10.0) 0.721 0.396
Myositis 1 (2.5) 0 (0.0) 1.013 0.314
ECLAM   4.7 ± 2.3 2.9 ± 1.4 4.326 <0.001
Laboratory features ESR (mm/1st hour) 54.6 ± 32.4 41.7 ± 26.9 1.942 0.056
Serum creatinine (μmol/L) 1.0 ± 0.7 0.6 ± 0.2 2.79 0.008
Serum albumin (g/dl) 3.6 ± 0.6 4.1 ± 0.7 3.895 < 0.001
24 h urinary proteins (g/24 h) 2 ± 1.7    
Low C3 < 90 26 (65.0) 10 (25.0) 12.929 < 0.001
Low C4 < 10 17 (42.5) 2 (5.0) 15.531 < 0.001
Anti-nucleosome antibody positivity 24 (60.0) 25 (62.5) 0.053 0.818
Anti-C1q antibody positivity 23 (57.5) 11 (27.5) 7.366 0.007
Renal biopsy Lupus nephritis class I 0 (0)
Lupus nephritis class II 5 (12.5)
Lupus nephritis class III 13 (32.5)
Lupus nephritis class IV 11 (27.5)
Lupus nephritis class V 3 (7.5)
Lupus nephritis class II- III 6 (15)
Lupus nephritis class II & V 2 (5)
  1. APS Antiphospholipid syndrome, ESR Erythrocyte sedimentation rate, ECLAM European Consensus Lupus Activity Measurement